Black Rock Inc. Trevi Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,135,115 shares of TRVI stock, worth $19.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,135,115

Previous 2,375,709 31.97%

Holding current value

$19.1 Million

Previous $8.2 Million 13.98%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.44 - $3.36 $1.85 Million - $2.55 Million	759,406 Added 31.97%	3,135,115 $9.34 Million
Q1 2024 May 10, 2024	BUY	$1.3 - $3.7 $72,790 - $207,174	55,993 Added 2.41%	2,375,709 $8.2 Million
Q4 2023 Feb 13, 2024	BUY	$1.06 - $2.05 $181,740 - $351,478	171,453 Added 7.98%	2,319,716 $3.11 Million
Q3 2023 Nov 13, 2023	SELL	$2.11 - $2.47 $182,721 - $213,897	-86,598 Reduced 3.87%	2,148,263 $4.68 Million
Q2 2023 Aug 11, 2023	BUY	$1.8 - $3.44 $3.87 Million - $7.4 Million	2,152,616 Added 2617.32%	2,234,861 $5.34 Million
Q1 2023 May 12, 2023	BUY	$1.69 - $2.97 $2,491 - $4,377	1,474 Added 1.82%	82,245 $152,000
Q4 2022 Feb 13, 2023	BUY	$1.61 - $2.42 $35,334 - $53,111	21,947 Added 37.31%	80,771 $155,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $4.28 $2,048 - $5,692	1,330 Added 2.31%	58,824 $90,000
Q2 2022 Aug 12, 2022	BUY	$1.8 - $3.39 $43,299 - $81,546	24,055 Added 71.94%	57,494 $161,000
Q1 2022 May 12, 2022	SELL	$0.46 - $2.48 $5,294 - $28,542	-11,509 Reduced 25.61%	33,439 $73,000
Q4 2021 Feb 10, 2022	BUY	$0.68 - $1.5 $713 - $1,573	1,049 Added 2.39%	44,948 $35,000
Q3 2021 Nov 09, 2021	SELL	$1.29 - $2.18 $362 - $612	-281 Reduced 0.64%	43,899 $61,000
Q2 2021 Aug 11, 2021	BUY	$2.0 - $2.76 $88,360 - $121,936	44,180 New	44,180 $99,000

Others Institutions Holding TRVI

# of Institutions

142

Shares Held

85.3M

Call Options Held

1.5M

Put Options Held

304K

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $355M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account